Table 3.
Number of genes altered as a function of the treatment type
| Treatment type | E | Cx10 | Gb | Cx10 + E | Gb + E | |||||
| Down | Up | Down | Up | Down | Up | Down | Up | Down | Up | |
| HT-29 | 855 | 544 | 465 | 287 | 1253 | 885 | 217 | 459 | 799 | 582 |
| Caco-2 | 1134 | 915 | 541 | 731 | 577 | 868 | 238 | 57 | 226 | 64 |
| Intersection | 274 | 124 | 58 | 49 | 113 | 138 | 3 | 0 | 32 | 10 |
E = Epidermal growth factor 10 nmol/L; Cx10 = cetuximab 10 nmol/L; Gb = gefitinib 1 μmol/L;
Cx10 + E = cetuximab 10 nmol/L + Epidermal growth factor 10 nmol/L; Gb + E = gefitinib 1 μmol/L + Epidermal growth factor 10 nmol/L; Down = 1/2 fold; Up = 2 fold.